Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Want to see TRVI full AI Analyst Report?
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$5.38 - $16.12
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.56M
Market Cap
$1.97B
Enterprise Value$1.99B
Total Cash (Recent Filing)$171.78M
Total Debt (Recent Filing)$682.00K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 06, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding141,979,700
10 Day Avg. Volume1,820,513
30 Day Avg. Volume2,561,308
Financial Highlights & Ratios
PEG Ratio1.11
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-58.58K
Enterprise Value/Ebitda-42.13
Forecast
1Y Price Target
$24.50Price Target Upside81.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Development Breadth And FundingPlans to initiate multiple late‑stage trials across fibrotic and other interstitial lung diseases, together with a solid cash position, support expansion of Haduvio's addressable market and the ability to execute the clinical program.
Regulatory ClarityFDA alignment on the remaining development requirements and on the pivotal program design provides a clear regulatory path for advancing Haduvio into pivotal studies, reducing approval uncertainty.
Trial Endpoint RobustnessAgreement to use an objective full‑day cough frequency measure as the primary endpoint, with patient‑reported outcomes as key secondary measures, strengthens trial interpretability and supports validation of prior efficacy signals.
Bears Say
Higher Development CostsRequirement to run two full pivotal trials along with additional phase one studies raises development complexity and is likely to increase trial costs and resource needs.
Near‑term Catalyst DroughtNo clinical trial readouts are expected in the near term, creating a gap in material catalysts and heightening short‑term investor uncertainty.
Timeline ExtensionRegulatory feedback that increases the expected time to data readouts and keeps key trials blinded delays visibility on results and weakens near‑term catalyst momentum.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $5.38 and its highest was $16.12 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $1.97B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 76 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on May 05, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.076 by -$0.014.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.1.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 141,979,700 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.076. Following the earnings report the stock price went down -2.729%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (81.89% Upside)
$24.50 (81.89% Upside)
Hedge Fund Trend
Decreased
By 997.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
232.05%
12-Months-Change
Fundamentals
Return on Equity
-24.53%
Trailing 12-Months
Asset Growth
67.85%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid execution progress: a strengthened balance sheet (pro forma cash ~ $334M) with runway into 2030, positive FDA alignment for IPF-related chronic cough, near-term trial initiations (Phase III IPF, Phase IIb RCC), an adaptive plan for non-IPF-ILD pending FDA agreement, expansion of IP filings and active scientific visibility (ATS, Investor Day). Principal risks discussed include competitor P2X3 readouts, possible trial upsizing via SSRE (and associated costs/timing), placebo variability in RCC, and regulatory dependence for the non-IPF-ILD program. On balance, the company presented multiple material positives and manageable risks tied to execution and external competitive/regulatory factors.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$24.50
▲(81.89% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
1.36% Insiders
15.38% Mutual Funds
53.52% Other Institutional Investors
20.64% Public Companies and
Individual Investors